Media Thread, page-17516

Hey GMT2 if we look at the Half Yearly there seems to be some mixed info first Paragraph says as at end of Dec 3 patients in the 1b trial achieved CR and that 2 of those demonstrated durable response.
So Aus patient not mentioned in that, as was dosed on 3rd Jan. Later it says total of seven patients treated 4 achieving CR so I think the Aus one counted in that as would have been evaluable in early Feb, anyway a little bit of a mixed message for a half yearly. Maybe they don't highlight different country results just overall results, although as mentioned it would have been good to highlight the Australian as first in the Aus arm of the trial.

They did say 4 at the tandem meeting and if you look closely at the poster they updated the days of durability for one of the patients to 294 as at the 13TH of Feb so day before presso, so a close call but the 28 days had passed and that is the first scan after treatment.



The trial is being conducted at 13 sites in the United States, and an expansion into Australia has commenced,
with the first patient enrolled at the Royal Prince Alfred Hospital in Sydney in early January 2025. Results at
the end of December 2024 show that three patients have achieved Complete Responses, including two
patients in Cohort B (azer-cel lymphodepletion (chemotherapy) and low-dose interleukin-2 (IL-2))
demonstrating durable responses beyond 90 and 120 days.
Another patient in Cohort A also achieved a Complete Response. Based on these results, the trial has
continued enrolling patients into Cohort B.


Then later in report it says
In February 2025 the Company announced more positive results from its Phase 1b trial evaluating azer-cel in
patients with relapsed/refractory DLBCL. In 7 patients treated in Cohort B (azer-cel, lymphodepletion and
low-dose interleukin-2), 4 (57%) achieved a Complete Response. All of these patients had previously failed
a minimum of four lines of therapy, including autologous CAR T therapy, suggesting azer-cel can offer a
beneficial therapy for DLBCL patients with a significant unmet need.
Imugene will continue enrolment in Cohort B and continue to monitor the long-term durability of these
responses to azer-cel.